Literature DB >> 17536990

Cerebral fat embolism syndrome causing brain death after long-bone fractures and acetazolamide therapy.

Criona M Walshe1, James D Cooper, Thomas Kossmann, Ivan Hayes, Linda Iles.   

Abstract

A 19-year-old woman with multiple fractures and mild brain injury developed severe cerebral fat embolism syndrome after "damage control" orthopaedic surgery. Acetazolamide therapy to manage ocular trauma, in association with hyperchloraemia, caused a profound metabolic acidosis with appropriate compensatory hypocapnia. During ventilator weaning, unexpected brainstem coning followed increased sedation and brief normalisation of arterial carbon dioxide concentration. Autopsy found severe cerebral fat embolism and brain oedema. In patients with multiple trauma, cerebral fat embolism syndrome is difficult to diagnose, and may be more common after delayed fixation of long-bone fractures. Acetazolamide should be used with caution, as sudden restoration of normocapnia during compensated metabolic acidosis in patients with raised intracranial pressure may precipitate coning.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17536990

Source DB:  PubMed          Journal:  Crit Care Resusc        ISSN: 1441-2772            Impact factor:   2.159


  3 in total

1.  Isolated and early-onset cerebral fat embolism syndrome in a multiply injured patient: a rare case.

Authors:  Chin-Kai Huang; Chih-Yuan Huang; Chia-Lung Li; Jui-Ming Yang; Chin-Hsien Wu; Chih-Hui Chen; Po-Ting Wu
Journal:  BMC Musculoskelet Disord       Date:  2019-08-17       Impact factor: 2.362

2.  Massive cerebral fat embolism leading to brain death: A rare presentation.

Authors:  Richa Aggarwal; Sugata Pal; Kapil Dev Soni; Shivanand Gamangatti
Journal:  Indian J Crit Care Med       Date:  2015-11

3.  Brain death due to fat embolism - could moderate hypercapnia and prone position be blamed for the tonsillar herniation?

Authors:  Rafael Kawati; Anders Larsson
Journal:  Ups J Med Sci       Date:  2013-08-27       Impact factor: 2.384

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.